Skip to main content

Table 2 Effects of SSR240612 treatments on cerebrovascular responses to ACh and BK

From: Cognitive and cerebrovascular improvements following kinin B1 receptor blockade in Alzheimer’s disease mice

SSR 5 weeks

WT (n = 4)

WT-SSR (n = 4)

APP (n = 4)

APP-SSR (n = 4)

ACh (EAmax)

57.2 ± 3.0

54.3 ± 2.5

34.2 ± 2.0 ††

50.1 ± 3.3**

ACh (pD2)

8.06 ± 0.2

8.19 ± 0.1

8.30 ± 0.2

7.91 ± 0.2

BK (max constr.)

−69.53 ± 13.2

−64.15 ± 7.3

−95.55 ± 16.4

−74.50 ± 8.3

BK (max dilat.)

−40.3 ± 11.4

−10.3 ± 6.4

−61.6 ± 18.1

−34.6 ± 12.6

SSR 10 weeks

WT (n = 4)

WT-SSR (n = 5)

APP (n = 5)

APP-SSR (n = 5)

ACh (EAmax)

51.2 ± 2.7

67.8 ± 3.3

32.5 ± 1.9 †

49.2 ± 3.2 *

ACh (pD2)

8.03 ± 0.1

7.79 ± 0.1

8.37 ± 0.18

8.17 ± 0.2

BK (max constr.)

−54.11 ± 6.4

−77.67 ± 7.8

−70.77 ± 7.5

−63.78 ± 9.2

BK (max dilat.)

−23.5 ± 5.5

−8.6 ± 9.2

−44.9 ± 8.3

−31.3 ± 9.8

  1. Data are means ± SEM from the number (n) of mice indicated in parentheses and expressed as the agonist maximal response (EAmax) or affinity (pD2, -log[EC50]). EAmax (%) is the maximal dilation to ACh. For agonist response to BK, both the maximal constriction and dilatation from the induced tone (%) are indicated. Values for BK are negative, the zero value being the induced tone. P <0.05, †† P <0.01 when compared to non-treated WT controls; * P <0.05, ** P <0.01 when compared to non-treated APP mice. SSR SSR240612, ACh acetylcholine, BK bradykinin, WT wild-type, APP amyloid precursor protein.